November 16th, 2026Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast CancerPertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.Read more
November 11th, 2026Breast Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in October 2026Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.Read more